Clinical Trial

Phase I Study of HBT-708 for Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 11, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study will be to evaluate the safety, tolerability, and inital efficacy of HBT-708 in subjects with advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-27.
Status change: Not Yet Recruiting → Recruiting 2025-07-08
Trial Details
NCT Number NCT06993870
Lead Sponsor Shenyang Sunshine Pharmaceutical Co., LTD.
Conditions Advanced Solid Tumors
Enrollment 60 participants
Start Date 2025-06-16
Primary Completion 2026-03-01 (estimated)
Study Completion 2027-06-28 (estimated)
Updated on ClinicalTrials.gov 2025-07-11